A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults
NCT06493461 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5
Last updated 2025-05-30
Summary
A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults
Conditions
- Pulmonary Arterial Hypertension (PAH)
Interventions
- BIOLOGICAL
-
HS135
HS135 is dosed subcutaneously
Sponsors & Collaborators
-
35Pharma Inc
lead INDUSTRY
Principal Investigators
-
Monique Champagne, M.Sc. · VP, Clinical Operations
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-23
- Primary Completion
- 2025-03-31
- Completion
- 2025-03-31
- FDA Drug
- Yes
Countries
- Canada
- Germany
Study Locations
More Related Trials
-
Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension
NCT05135000 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
NCT06649110 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension
NCT05343637 ·Status: COMPLETED ·Phase: PHASE2
-
A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
NCT03657095 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
NCT00091715 ·Status: COMPLETED ·Phase: PHASE3
-
Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension
NCT01066845 ·Status: COMPLETED
-
A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension
NCT00853112 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
NCT05036135 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study
NCT06753981 ·Status: RECRUITING
-
This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
NCT03754660 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension
NCT03738150 ·Status: COMPLETED ·Phase: PHASE2
-
Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan
NCT02042014 ·Status: COMPLETED ·Phase: PHASE3
-
FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
NCT00760916 ·Status: WITHDRAWN ·Phase: PHASE3
-
Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension
NCT00185315 ·Status: COMPLETED ·Phase: PHASE3
-
Iloprost Power Disc-15 in Pulmonary Arterial Hypertension
NCT00723554 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist
NCT05427162 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants
NCT04955990 ·Status: TERMINATED ·Phase: PHASE4
-
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
NCT01560624 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
NCT02545465 ·Status: COMPLETED
-
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
NCT01894035 ·Status: COMPLETED
-
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
NCT02725372 ·Status: TERMINATED ·Phase: PHASE3
-
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
NCT01725256 ·Status: TERMINATED ·Phase: PHASE2
-
An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)
NCT01338636 ·Status: COMPLETED ·Phase: PHASE4
-
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
NCT01392495 ·Status: TERMINATED ·Phase: PHASE3
-
Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529
NCT01342952 ·Status: COMPLETED ·Phase: PHASE2